High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients

Journal of Neuroimmunology

Volumn 190, Issue 1-2, 2007, Pages 121-126

  Gladstone, Douglas E ^a   Golightly, Marc G ^b   Brannagan III, Thomas H ^c  

^a Hematology Oncology Associates of Western Suffolk   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

CD4RA+; CD4RO+; Chronic inflammatory demyelinating polyneuropathy; High dose cyclophosphamide; Multiple sclerosis

Indexed keywords

AZATHIOPRINE; CD4 ANTIGEN; CD45 ANTIGEN; CD45RA ANTIGEN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; STEROID;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ASSESSMENT; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIGENS, CD45; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RECOVERY OF FUNCTION; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 35448938790     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.07.005     Document Type: Article

References (18)

1. Brannagan III T.H., Pradhan A., Heiman-Patterson T., Winkelman A.C., Styler M.J., Topolsky D.L., Crilley P.A., Schwartzman R.J., Brodsky I., and Gladstone D.E. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 58 (2002) 1856-1858
2. Brannagan III T.H., Alaedini A., and Gladstone D.E. High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy. Muscle Nerve 34 (2006) 246-250
3. Drachman D.B., Jones R.J., and Brodsky R.A. Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide. Ann. Neurol. 53 (2003) 29-34
4. Gladstone D.E., Brannagan III T.H., Schwartzman R.J., Prestrud A.A., and Brodsky I. High dose cyclophosphamide for severe refractory myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 75 (2004) 789-791
5. Gladstone D.E., Prestrud A.A., Brannagan III T.H., Schwartzman R.J., and Brodsky I. High-dose cyclophosphamide for severe, refractory myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 75 (2004)
6. Gladstone D.E., Prestrud A.A., and Brannagan III T.H. High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J. Peripher. Nerv. Syst. 10 (2005) 11-16
7. Gladstone D.E., Zamkoff K.W., Krupp L., Peyster R., Sibony P., Christodoulou C., Locher E., and Coyle P.K. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch. Neurol. 63 (2006) 1388-1393
8. Karp C.L., van Boxel-Dezaire A.H., Byrnes A.A., and Nagelkerken L. Interferon-beta in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10?. Curr. Opin. Neurol. 14 (2001) 361-368
9. Koller H., Kieseier B.C., Jander S., and Hartung H.P. Chronic inflammatory demyelinating polyneuropathy. N. Engl. J. Med. 352 (2005) 1343-1356
10. Lucchinetti C., Bruck W., and Noseworthy J. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr. Opin. Neurol. 14 (2001) 259-269
11. Morimoto C., Letvin N.L., Distaso J.A., Aldrich W.R., and Schlossman S.F. The isolation and characterization of the human suppressor inducer T cell subset. J. Immunol. 134 (1985) 1508-1515
12. Muraro P.A., Pette M., Bielekova B., McFarland H.F., and Martin R. Human autoreactive CD4+ T cells from naive CD45RA+ and memory CD45RO+ subsets differ with respect to epitope specificity and functional antigen avidity. J. Immunol. 164 (2000) 5474-5481
13. Pestronk A., Drachman D.B., and Adams R.N. Treatment of ongoing experimental myasthenia gravis with short term high dose cyclophosphamide. Muscle Nerve 5 (1982) 79-84
14. Prestrud A.A., and Gladstone D.E. Quality of life after high-dose cyclophosphamide in patients with severe autoimmune diseases. J. Eval. Clin. Pract. 11 (2005) 411-416
15. Saccardi R., Mancardi G.L., Solari A., Bosi A., Bruzzi P., Di Bartolomeo P., Donelli A., Filippi M., Guerrasio A., Gualandi F., La Nasa G., Murialdo A., Pagliai F., Papineschi F., Scappini B., and Marmont A.M. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 105 (2005) 2601-2607
16. Saccardi R., Mancardi G.L., and Tyndall A. Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Report of the European Blood and Marrow Transplantation Group (EBMT) (2005), American Society of Hematology, Atlanta, Georgia
17. Samijn J.P., te Boekhorst P.A., Mondria T., van Doorn P.A., Flach H.Z., van der Meche F.G., Cornelissen J., Hop W.C., Lowenberg B., and Hintzen R.Q. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 77 (2006) 46-50
18. Stewart C.C., and Stewart S.F. Multiparameter Analysis of Leukocytes by Flow Cytometry (1994), Academic Press, San Diego